Efforts have been made to lay down analytical standards for Mehamudgara vati (MMV), which were not found reported till date. Weight variation showed that 90% tablets of MV manufactured in the Gujarat Ayurved University Pharmacy were within acceptable range (323 mg ± 10%), pH 4.58, and disintegration time 17 min, whereas hardness was 1.25 kg/cm2. Loss on drying was found to be 9.3% w/w, acid insoluble ash was 0.9 %w/w, water soluble extract was 24.06% w/w and methanol soluble extract 14.1% w/w. Determination of iron as Fe2O3 was done as Lauha bhasma being the major ingredient of MMV. The result showed that iron content was reduced in the formulation (28.67%) as compared to that in Lauha bhasma (61.19%). In TLC, 5 spots each at 254 nm and 366 nm were found.
Lauha-bhasma; Mehamudgara vati; standardization; thin layer chromatography
Diabetic nephropathy is a specific form of renal disease. It is a major cause of renal insufficiency and ultimately of death. The present study has been carried out to prove the efficacy of Ayurvedic drugs in the management of diabetic nephropathy, which can be helpful in reducing the need of dialysis and avoiding or delaying renal transplantation. A total of 130 patients of this disease were treated in IPD (Group A) and OPD (Group B). Ayurvedic formulations including Gokshuradi Guggulu, Bhumyamalaki, Vasa and Shilajatvadi Vati were given to all the patients for 2 months. Group A patients were given special planned food. Results were analyzed statistically using “t” test. In group A patients, highly significant reduction was found in the values of serum creatinine, blood urea and urinary excretion of albumin. Marked improvement was found in the patients’ general physical well-being, together with reduction in symptoms, in group A patients. This shows the importance of Pathyapathya in Ayurvedic management of the disease. This management may bring some new hope to the patients of diabetic nephropathy, which usually terminates to chronic renal failure and ultimately to death. Further studies are being carried out in this regard.
Ayurveda; diabetic nephropathy; albuminuria
To compare the effect of shodhan purvak shaman & shaman chikitsa in management of aamvata.
Above study was planned in two parts conceptual & clinical For clinical part 40 patients having disease aamvata were randomly selected from opd & ipd & were divided in two groups. In shodhan purvak shaman group shodhan basti & shaman vati were given. Which was selected from classic text of ayurveda. In Shaman group only shaman yog vati was administered to the patients. Total duration of treatment in both groups was of 8 weeks.
Shodhan purvak shaman therapy has given complete remission in 6 patients, major improvement was found in 9 patients, 4 patients in minor improvement category and one in un improved category. In shaman therapy complete relief was found in 3 patients, major improvement in 12 patients, in minor improved category there were 5 patients no patient was found in unimproved category.
The results thus obtained were subjected to analytical statistical techniques to compare both modes of treatments. Critical assessment of total effect of therapies on individual patient reflects that shodhan therapy along with shaman vati was more effective in pacifying the symptoms of disease aamvata & bringing down the level of disease activity also as compared to shaman therapy alone. Mode of action of drug is discussed. No side effects were seen.
A study has been designed to evaluate the effectiveness of Dashanga Kwatha Ghana Vati in Urdhwaga Amlapitta (non-ulcer Dyspepsia). Randomized single blind, placebo controlled study was conducted in 138 patients attending O.P.D. of department of Basic Principles, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, and grouped into two. Both the groups consumed two tablets of either Dashanga Kwatha Ghana Vati or placebo, twice daily after food for a period of eight weeks. The patients were followed upto four weeks, 110 patients had completed the treatment and no adverse effects were reported during the treatment. Both groups had improved in the clinical symptoms and overall statistical significance was observed in the differences of scores between the two groups.
Dashanga Kwatha Ghana Vati; non-ulcer dyspepsia; Urdhwaga Amlapitta
The desire to have a healthy progeny is innate & very intense in every living being. The hectic life and tremendous stress in today's world has made the conception & continuation of pregnancy to term very difficult. Anaemia is one of the common disease conditions which affect a pregnant woman. In Ayurvedic classics anaemia in pregnancy is taken under the Rasa Pradoshaja Vikara. It is also a Santharpanotha Vikara.
Total 26 patients were registered from O.P.D. And I.P.D. of the department of Streeroga & Prasootitantra, out of them 4 patients were discontinued. They were randomly divided in to two groups; Group A (n 12) Pandughni Vati 2 tablets of 250mg tds and Group B (n 10) Dhatri Lauha Vati 1 tablet of 250mg tds. Dhatri Lauha Vati was selected for the present study due to its Pandughna, Prinana, Raktaprasadana properties. AYUSH department has developed a compound formulation Pandughni Vati. As a part of its clinical trials the same drug was selected for present study.
Group A The result observed in Shwasa (dyspnoea) (60%) and Hridrava (palpitation) (53.33%) were highly significant statistically (<0.001). Daurbalya (33.33%), Shrama (fatigue) (40%), Aruchi (anorexia) (28.57%) and Pindikodvestana (55.55%) were decreased significant statistically (<0.05) whereas in Panduta (pallor) (24%) it was not significant. In Group B, results observed were highly significant statistically (<0.001) in Panduta (pallor) (50%) and Shwasa (dyspnoea) (56.25%). The results in Shrama (fatigue) (61.54%), Hridrava (palpitation) (55.55%), Aruchi (anorexia) (42.85%), Pindikodvestan, (49.49%) were significant
On comparing the effect of therapy study was finding better percentage improvement in-group B consistently in most of subjective and objective parameters. So it can be said that Dhatri Lauha Vati has somewhatbetter results, proving it better to Pandughni Vati.
Hyperlipidemia is a major risk factor of coronary heart disease. Currently available hypolipidemic drugs have been associated with number of side effects. Arogyavardhini vati, an Ayurvedic polyherbal formulation has been used for liver disorders. Therefore, present study was designed to evaluate the effect of Arogyavardhini vati in Triton WR-1339-induced hyperlipidemia in rats.
Anti-hyperlipidemic activity evaluation of Arogyavardhini vati against Triton WR-1339-induced hyperlipidemia in rats.
Materials and Methods:
Overnight fasted male Wistar rats (150-200 g) were randomly divided into normal control group [4% Dimethyl Sulfoxide (DMSO), i.p.], positive control group (Triton WR-1339 in 4% DMSO, 400 mg/kg, i.p.), standard drug treated (fenofibrate 65 mg/kg, p.o. for 7 days after inducing hyperlipidemia) and Arogyavardhini vati treated (50, 100, 200 mg/kg, p.o. for 7 days after inducing hyperlipidemia). Rat doses were calculated by extrapolating the equivalent human dose (therapeutic dose, sub-maximum, and maximum dose). Serum total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein HDL, liver malondialdehyde (MDA), and glutathione (GSH) levels were estimated at end of experiments.
Arogyavardhini vati significantly decreased serum cholesterol, triglyceride, LDL, and C-reactive protein (CRP) and significantly increased serum HDL in a dose-dependent manner. Decreased MDA and increased GSH levels in liver were observed at all doses of Arogyavardhini vati (50, 100, 200 mg/kg) and fenofibrate-treated groups when compared with Triton-treated group. Atherogenic Index (AI) level was significantly decreased in fenofibrate and Arogyavardhini vati (200 mg/kg) treated rats when compared with normal control.
Arogyavardhini vati, a traditionally used Ayurvedic medicine may be a useful therapy for hypercholesterolemia through reducing oxidative stress (decreasing MDA and increasing GSH) and lipid levels.
Arogyavardhini vati; atherogenic index; hypolipidemia; oxidative stress; Triton WR-1339
Mice minute virus (MMV) and mouse parvovirus (MPV) type 1 are the two parvoviruses known to naturally infect laboratory mice and are among the most prevalent infectious agents found in contemporary laboratory mouse colonies. Serologic assays are commonly used to diagnose MMV and MPV infections in laboratory mice; however, highly accurate, high-throughput serologic assays for the detection of MMV- and MPV-infected mice are needed. To this end, the major capsid viral protein (VP2) genes of MMV and MPV were cloned and MMV recombinant VP2 (rVP2) and MPV rVP2 proteins were expressed by using a baculovirus system. MMV rVP2 and MPV rVP2 spontaneously formed virus-like particles that were morphologically similar to empty parvovirus capsids. These proteins were used as antigens in enzyme-linked immunosorbent assays (ELISAs) to detect anti-MMV or anti-MPV antibodies in the sera of infected mice. Sera from mice experimentally infected with MMV (n = 43) or MPV (n = 35) and sera from uninfected mice (n = 30) were used to evaluate the ELISAs. The MMV ELISA was 100% sensitive and 100% specific in detecting MMV-infected mice, and the MPV ELISA was 100% sensitive and 98.6% specific in detecting MPV-infected mice. Both assays outperformed a parvovirus ELISA that uses a recombinant nonstructural protein (NS1) of MMV as antigen. The MMV rVP2 and MPV rVP2 proteins provide a ready source of easily produced antigen, and the ELISAs developed provide highly accurate, high-throughput assays for the serodiagnosis of MMV and MPV infections in laboratory mice.
The present study was conducted on 30 clinically diagnosed and confirmed patients of Coronary Artery Disease (C.A.D.). Patients having C.A.D. with specific conditions were not registered. The study was conducted with an objective of evaluating the role of Prabhakara Vati and Lekhana Basti in the management of C.A.D. on various scientific parameters.
30 patients were randomly divided into three groups. It was a randomised, comparative, open ended, pre and post design, clinical trial. Out of the three groups, 10 patients were administered Tab. Dilzem 30 mg TDS for one month, 10 patients of second group were administered Prabhakara Vati 500 mg (two tablets) bd for one month and 10 patients were administered Lekhana Basti (for 15 days) along with Prabhakara Vati 500 mg (two tablets) bd for one month.
During present trial it was observed that there was significant improvement in clinical manifestations of stable angina after the therapy with Prabhakara Vati and Lekhana Basti. The level of S. Cholesterol, L.D.L., V.L.D.L. and Serum Triglycerides decreased and the level of H.D.L. increased considerably after the therapy.
Prabhakara Vati and Lekhana Basti possesses potent antianginal and cardio protective activities and it can be used effectively in the management/to slow down the progress of pathogenesis of atherosclerosis leading to various Hridrogas (C.A.D.) specially stable angina.
The present study was aimed to assess the clinical effectiveness of Rasona Rasnadi Ghanavati and Simhanada Guggulu along with Rasona Rasnadi Lepa in Amavata, and to compare the effect of these two therapies in the treatment. Total 101 patients of Amavata were registered for the present study and were randomly divided into two groups. In group A- Rasona Rasnadi Ghanavati 2 Vati thrice/day was given for 3 months, while in group B- Simhanada Guggulu 2 Vati thrice a day for 3 months was adminstered. Along with this, Rasona Rasnadi Lepa was applied locally over affected joints twice daily in both groups. The effects of therapy in both groups were assessed by a specially prepared proforma. The results of the study showed that both the groups showed significant relief in symptoms; however, compared to Simhanada Guggulu, Rasona Rasnadi Ghanavati showed better result in the management of Amavata. Simhanada Guggulu or Rasona Rasnadi Ghanavati along with Rasona Rasnadi Lepa can be used as an effective ayurvedic intervention in the treatment for rheumatoid arthritis.
Ama; Amavata; Rasona Rasnadi Ghanavati; Rheumatoid arthritis; Simhanada Guggulu; Vata
This work addresses the problem of recovering multi-echo T1 or T2 weighted images from their partial K-space scans. Recent studies have shown that the best results are obtained when all the multi-echo images are reconstructed by simultaneously exploiting their intra-image spatial redundancy and inter-echo correlation. The aforesaid studies either stack the vectorised images (formed by row or columns concatenation) as columns of a Multiple Measurement Vector (MMV) matrix or concatenate them as a long vector. Owing to the inter-image correlation, the thus formed MMV matrix or the long concatenated vector is row-sparse or group-sparse respectively in a transform domain (wavelets). Consequently the reconstruction problem was formulated as a row-sparse MMV recovery or a group-sparse vector recovery. In this work we show that when the multi-echo images are arranged in the MMV form, the thus formed matrix is low-rank. We show that better reconstruction accuracy can be obtained when the information about rank-deficiency is incorporated into the row/group sparse recovery problem. Mathematically, this leads to a constrained optimization problem where the objective function promotes the signal's groups-sparsity as well as its rank-deficiency; the objective function is minimized subject to data fidelity constraints. The experiments were carried out on ex vivo and in vivo T2 weighted images of a rat's spinal cord. Results show that this method yields considerably superior results than state-of-the-art reconstruction techniques.
MRI reconstruction; compressed sensing; low-rank matrix recovery
To assess the effect of a comprehensive yogic breathing program on glycemic control and quality of life (QOL) in patients with diabetes.
Materials and Methods:
This is a prospective randomized controlled intervention trial. Patients having HbA1c between 6 and 9% for at least 3 months with lifestyle modification and oral antidiabetic medication were included. They were followed-up and randomized at 6 months into two groups: one group receiving standard treatment of diabetes and the other group receiving standard treatment of diabetes and taught and told to regularly practice the comprehensive yogic breathing program (Sudarshan Kriya Yoga and Pranayam). Change in fasting and post-prandial blood sugars, glycated hemoglobin and QOL as assessed by the World Health Organization QOL WHOQOL BREF questionnaire were assessed.
There was a trend toward improvement in glycemic control in the group practicing the comprehensive yogic breathing program compared with the group following standard treatment alone, although this was not significant. There was significant improvement in physical, psychological and social domains and total QOL post-intervention in the group practicing the comprehensive yogic breathing program as compared with the group following standard treatment alone.
There was significant improvement in the QOL and a non-significant trend toward improvement in glycemic control in the group practicing the comprehensive yogic breathing program compared with the group that was following standard treatment alone.
Comprehensive yogic breathing program; diabetes mellitus; quality of life
Hypertension is the most common psychosomatic disorder affecting 972 million people worldwide. The present clinical study deals with the effect of Makandi (Coleus forskohlii (Willd.) Briq.) Ghana vati and tablets of its powder in hypertension found in the geriatric age group (50-80 years). A total of 49 hypertensive patients fulfilling the diagnostic criteria were registered in two groups-Group I (Ghana vati) and Group II (Churna tablet). Out of 27 enrolled patients of group I, 21 patients completed the treatment. In Group II, out of 22 registered patients, a total of 20 patients completed the treatment. The effect of the therapy was assessed on the basis of changes in the systolic and diastolic blood pressures, in both sitting and supine positions; with Manasa Bhava Pariksha, Manasa Vibhrama Pariksha, symptomatology, geriatric signs and symptoms, and a brief psychiatric rating scale. Analysis of the results showed that the treatment in both the groups had been found to be good. It can be stated that Makandi, either in Ghana vati form or in churna tablet form, is an effective remedy for the treatment of hypertension. On analyzing the overall effect, 76.19% patients in Group I and 75.00% patients in Group II were mildly improved. Comparatively the overall treatment with group I was found to be better.
Makandi; Coleus forskohlii; forskolin; Ghana vati; geriatric hypertension
Childhood period is considered as the period of rapid growth and development, as it is the crucial stage of establishing future. Gastro-intestinal disorders show high prevalence in pediatric practice. These conditions generally produce chronic illness. Grahanidosha is a disease related with Agnidushti. This condition is seen more in childhood period due to faulty dietary habit and changing lifestyle. The present paper deals with study on etiopathogenesis of Grahanidosha and evaluates the efficacy of Deavadarvyadi-Vati. The etiological factors and symptoms were observed carefully to make clear etiopathogenesis. Total 32 patients (3-12 years) were registered and randomly divided into two groups. In Group A Devadarvyadi-Vati (treated group) and in Group B Bhunimbadi-Vati (control group) given for 4 weeks with Koshna Jala. In Group A (Devadarvyadi-Vati), marked improvement was observed in 21.43% of the patients, moderate improvement was observed in 57.14% of patients and mild improvement was observed in 21.43% of patients.
Bhunimbadivati; Devadarvyadivati; Grahani Dosha
Lymphocyte microvilli mediate initial adhesion to endothelium during lymphocyte transition from blood into tissue but their molecular organization is incompletely understood. We modified a shear-based procedure to prepare biochemical fractions enriched for membrane/microvilli (MMV) from both human peripheral blood T-lymphocytes (PBT) and a mouse pre-B lymphocyte line (300.19). Enrichment of proteins in MMV relative to post nuclear lysate was determined by LC/MS/MS analysis and label-free quantitation. Subsequent analysis emphasized the 291 proteins shared by PBT and 300.19 and estimated by MS peak area to be highest abundance. Validity of the label-free quantitation was confirmed by many internal consistencies and by comparison with Western blot analyses. The MMV fraction was enriched primarily for subsets of cytoskeletal proteins, transmembrane proteins and G-proteins, with similar patterns in both lymphoid cell types. The most enriched cytoskeletal proteins were microfilament-related proteins NHERF1, Ezrin/Radixin/Moesin (ERMs), ADF/cofilin and Myosin1G. Other microfilament proteins such as talin, gelsolin, myosin II and profilin were markedly reduced in MMV, as were intermediate filament- and microtubule-related proteins. Heterotrimeric G-proteins and some small G-proteins (especially Ras and Rap1) were enriched in the MMV preparation. Two notable general observations also emerged. There was less overlap between the two cells in their transmembrane proteins than in other classes of proteins, consistent with a special role of plasma membrane proteins in differentiation. Second, unstimulated primary T-lymphocytes have an unusually high concentration of actin and other microfilament related proteins, consistent with the singular role of actin-mediated motility in the immunological surveillance performed by these primary cells.
Lymphocyte microvilli initiate adhesion to endothelium during movement from blood into tissue. Using LC/MS/MS and label-free quantitation, we identify proteins enriched in membrane/microvilli (MMV) fractions from lymphocytes (primary human T-lymphocytes and mouse pre-B lymphocyte line). The cytoskeletal proteins most enriched in both lymphocyte types are microfilament-related proteins NHERF1, Ezrin/Radixin/Moesin (ERMs), ADF/cofilin and Myosin1G. Heterotrimeric G-proteins and some small G-proteins (especially Ras and Rap1) are also enriched. Complementary approaches provide confirmation.
lymphocyte; microvillus; proteome; LC-MS/MS; label-free quantitation; cytoskeleton; small-GTP-binding protein; Myo1G; NHERF1; cofilin
The Malaria Clinical Trials Alliance (MCTA), a programme of INDEPTH network of demographic surveillance centres, was launched in 2006 with two broad objectives: to facilitate the timely development of a network of centres in Africa with the capacity to conduct clinical trials of malaria vaccines and drugs under conditions of good clinical practice (GCP); and to support, strengthen and mentor the centres in the network to facilitate their progression towards self-sustaining clinical research centres.
Sixteen research centres in 10 African malaria-endemic countries were selected that were already working with the Malaria Vaccine Initiative (MVI) or the Medicines for Malaria Venture (MMV). All centres were visited to assess their requirements for research capacity development through infrastructure strengthening and training. Support provided by MCTA included: laboratory and facility refurbishment; workshops on GCP, malaria diagnosis, strategic management and media training; and training to support staff to undertake accreditation examinations of the Association of Clinical Research Professionals (ACRP). Short attachments to other network centres were also supported to facilitate sharing practices within the Alliance. MCTA also played a key role in the creation of the African Media & Malaria Research Network (AMMREN), which aims to promote interaction between researchers and the media for appropriate publicity and media reporting of research and developments on malaria, including drug and vaccine trials.
In three years, MCTA strengthened 13 centres to perform GCP-compliant drug and vaccine trials, including 11 centres that form the backbone of a large phase III malaria vaccine trial. MCTA activities have demonstrated that centres can be brought up to GCP compliance on this time scale, but the costs are substantial and there is a need for further support of other centres to meet the growing demand for clinical trial capacity. The MCTA experience also indicates that capacity development in clinical trials is best carried out in the context of preparation for specific trials. In this regard MCTA centres involved in the phase III malaria vaccine trial were, on average, more successful at consolidating the training and infrastructure support than those centres focussing only on drug trials.
Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role. Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. Total of 108 patients were screened at CGHS Ayurvedic Hospital, New Delhi. Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder (5 g, BD) for 3 weeks and then Arogyavardhini Vati (500 mg, BD) for 4 weeks were prescribed to the patients. The primary efficacy endpoint was reduction in serum total cholesterol, LDL, triglycerides, and increased HDL levels. Secondary endpoints included reduction in serum C-Reactive Protein (CRP) and blood glucose levels. Safety assessments included hepatic function (aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, and β2 microglobulin), renal function (urea and creatinine and NGAL) tests, and urine mercury level. The study was completed by 87 patients. The male and female patients were 65.5% (57/87) and 34.5% (30/87), respectively. There was a significant reduction in total cholesterol, LDL, triglycerides, CRP, and blood glucose. However, raised HDL level was also observed. Safety assessment results showed no significant change in serum ALT, AST, ALP and bilirubin, urea, creatinine β2 microglobulin, and NGAL levels at the end of study as compared to the baseline levels. In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia.
Arjuna; Arogyavardhini Vati; dyslipidemia; efficacy; safety
Klaibya (Male Sexual Dysfunction = MSD) is common among men of all ages, it has been recently estimated that more than 152 million men worldwide experienced sexual dysfunction in 1995, and that this number will rise by 170 million, to approximately 322 million by the year 2025. In the past years, it has been reported that most of the hypertensive patients having disability to perform sexual acts and comes under the MSD. To keep these facts in mind the present study aimed to evaluate the efficacy of the Gokshuradi Vati in the management of Klaibya with or without hypertension.
The patients identified and classified as suffering from klaibya with or without hypertension participated in the clinical trial in three groups. The trial drug Gokshuradi Vati (Su.) 2 tabs of 500 mg with anupana of GOKSURADI KWATHA 10 ml. was be administered to all the patients for 1 month. All the Patients were assessed on the basis of subjective and objective criteria.
The results showed statistically significant improvement in high blood pressure. Beside these, highly significant improvement was found in sperm count, serum testosterone level and IIEF-15 variables.
On the basis of the results this study concluded that hypertension and klaibya are having a strong relation in each other's pathogenesis. On the basis of our study, we can say that every patient of hypertension should be examined for Klaibya.
To examine the effect of “DeepaniyaVati”, a herbal formulation in the management of hyperlipidemia, a randomized group pre-test post-test study trial was carried out on fifty male (30 to 70 yrs) hyperlipidemic volunteers who were asked to follow their normal routine diet and activity pattern throughout the investigation period. The formulation, prepared by mixing nine plant products in equal proportion, when given in a daily dose of 2g, twice a day for a period of one month, brought about an observable improvement in all the lipid parameters by significantly reducing total cholesterol (10%), low density lipoprotein cholesterol (12.76%), very low density lipoprotein cholesterol (27.4%), triglycerides (34.7%) and bringing these values much nearer to the normal levels. In control group, no such effect was noticed. A concomitant significant increase in the HDL-C levels suggests the possible utility of “Deepaniya Vati” in the management of hyperlipidemia and the need for further detailed study.
Hyperlipidemia; herbal formulation; lipoproteins; cholesterol; triglycerides
In the present clinical study, 63 patients of Amavata were registered from the Kayachikitsa out patient department/indoor patient department (OPD/IPD) of Sir Sunder Lal Hospital (Indian Medicine Wing), IMS, BHU, Varanasi-5. In group I (Rasona Pinda), 27 patients completed the study of a total of 33patients registered in the group (six patients dropped out mid–therapy). In group II (control group), 23 patients completed all three follow-ups out of 30 patients (there were seven dropouts in mid–therapy). In group I, complete remission in 29.6%, major improvement in 59.3% and minor improvement in change font so as to appear 11.1% were observed. In group II, complete remission in 13%, major improvement in 21.7%, minor improvement in 39.1% and unchanged in 26.9% of the patients were observed.
Amavata; Rheumatoid Arthritis; Agni; Ama; Rasona Pinda; Visual Analog Scale
Studies have shown that diabetes is accompanied by an increased oxidative damage to all the bimolecular. Enhanced oxidative stress contributes to the development of the diabetic complications. The key lipid soluble chain breaking antioxidant,-tocopherol, is known to be deficient in diabetes. Human intervention studies have indicated the role of vitamin E in improving the endothelial function, the retinal blood flow and the renal dysfunction. The aim of the study was to find the role of vitamin E in preventing the development and the progression of the diabetic complications.
Both type I and II DM patients with and without complications were included in this study. They were divided separately into the test (which received insulin/oral hypoglycemic and vitamin E) and the control groups (which received only insulin/oral hypoglycemic drugs). The Fasting Blood Sugar(FBS), Post-prandial Blood Sugar(PPBS) and the Total Cholesterol(TC) were estimated and the Blood Pressure (BP) was noted at 0(beginning),12,18 and 24 months. Cardiovascular disease, retinopathy, nephropathy and foot ulcer development and progression were monitored. The data was analyzed by the Z test for the means and for the proportions.
It was evident from the analysis of the data that the PPBS, TC and the Diastolic Blood Pressure (DBP) declined gradually and significantly in the test groups. This was a beneficial development for the diabetic patients. The patients who were on the vitamin E supplementation had a delayed development and a slow progression of the complications.
Vitamin E supplementation has an important role in delaying the onset of the diabetic complications as well as for slowing down the progression of the complications
Diabetes mellitus; Antioxidant; Diabetic complications
Amlapitta is a disease caused by increase of Amla Guna of Pitta. Starch obtained from the rhizomes of two plants viz., Curcuma angustifolia Roxb. (Fam. Zingiberaceae) and Maranta arundinacea Linn. (Fam. Marantaceae) are used as Tugaksheeree. In the present clinical study, the efficacy of Tugaksheeree was studied on 67 patients of Amlapitta. A 0 total of 84 patients suffering from Amlapitta were selected from the O.P.D. and I.P.D. sections in the department of Dravyaguna, I.P.G.T. and R.A., Hospital, Jamnagar, and were randomly divided into two groups. Thirty four patients completed the treatment course in Group I, and 33 patients completed the treatment course in Group II. The efficacy of drug Tugaksheeree was studied through internal administration of the starches of C. angustifolia Roxb. (Fam. Zingiberaceae) in Group I and M. arundinacea Linn. (Fam. Marantaceae) in Group II with the dose of 4 g TID with water for 30 days. Both the drugs were found highly effective in treating Amlapitta. They significantly relieved the cardinal symptoms viz., Avipaka, Tikta-amlodgara, Daha, Shoola, Chhardi and the associated symptoms viz., Aruchi, Gaurava, Udaradhmana, Antrakujana, Vit bheda, Shiroruja, Angasada, and Trit. Statistically significant increase in body weight was noticed in both the groups. This may be because the drugs corrected the Agni and acted as Brihmana and Dhatupushtikara. Both the drugs did not produce any side effects. Therefore, both these drugs (C. angustifolia Roxb. and M. arundinacea Linn.) can be used as substitutes for each other.
Tugaksheeree; Curcuma angustifolia Roxb. and Maranta arundinacea Linn. Starch; Amlapitta
The study aims to evaluate the effect of zinc sulfate on markers of glycemic control, lipid profile and inflammation in type-2 diabetes with microalbuminuria patients.
Materials and Methods:
Type-2 diabetes with microalbuminuria patients on oral hypoglycemic agents (OHA) and angiotensin converting enzyme (ACE) inhibitors were selected and divided into 2 groups: One group (n = 27) continued with OHA alone, second group (n = 27) was on OHA and in addition 50 mg elemental zinc as zinc sulphate supplementation for 12 weeks. Fasting, post-prandial blood glucose, glycosylated hemoglobin, lipid profiles, inflammatory marker hs-CRP and urine microalbumin were measured.
There were no significant differences in biochemical status among groups at baseline. After receiving zinc, the mean fasting blood glucose (FBS), post-prandial blood glucose (PPBS) and glycosylated hemoglobin (HbA1c) were decreased significantly (P = 0.0001). Significant decrease was observed in TG (P = 0.002) and VLDL-cholesterol (P = 0.002), whereas there was no significant decrease in TC and LDL-cholesterol. The high-density lipoprotein (HDL) cholesterol was significantly (P = 0.0001) increased from baseline. Zinc supplementation had significant effects in decreasing serum hs-CRP from 10.51 ± 1.68 mg/L to 7.75 ± 1.56 mg/L (P = 0.0001) and microalbumin level from 146.87 ± 30.83 mg/day to 80.70 ± 33.99 mg/day (P = 0.0001). There were no significant changes in the levels of all these parameters in OHA group.
Our results conclude that supplementation of zinc improved the effectiveness of OHA and may be beneficial in decreasing blood glucose, TG, urinary albumin excretion and inflammation in diabetic nephropathy patients and thus reducing the risk of complications.
Glycemic control; inflammation; microalbuminuria; type-2 diabetes; zinc sulphate
Grahani and Agni are having Adhara-Adheya-Sambandha. Grahani is described as an Agni Adhishthana by most of the acharyas. Mandagni is a root cause of Ama Dosha and it is the crucial factor for manifestation of most of the diseases. Among them, Grahani is the prime disease of gastro-intestinal tract and seen often in day-to-day practice. A total of 66 patients were randomly divided in three groups and treated with: A) Kalingadi Ghanavati, three vatis of 500 mg twice daily with takra, B) Tryushnadi Ghrita, 10 g twice daily before meal with lukewarm water and C) Combination of both the drugs for 14 days. An assessment was done on the basis of Rogabala, Dehabala, Agnibala, and Chetasabala. The study revealed that combination proved better results than those of individuals.
Ama Dosha; Grahani Roga; Agni; Kalingadi Ghanavati; Tryushnadi Ghrita; Rogabala; Dehabala; Agnibala; Chetasabala
Diabetes mellitus is a common chronic metabolic disorder prevalent all over the world. Virechana is the Shodhana procedure that is specific for the elimination of vitiated Pitta and Kapha doshas. Thus, in the present study, the Virechana process has been selected prior to the administration of Shamana drug. Nyagrodhadi churna is mentioned in Chakradatta, which is modified into Ghana form for easy administration and dose maintenance. The present study was conducted in two groups: Group A, Nyogrodhadi Ghana vati (Shamana therapy) and Group B, Virechana and Nyogrodhadi Ghana vati (combined therapy). A total of 42 patients were registered for the present study, in which 34 patients completed the and eight patients were dropouts. After evaluating the total effect of the therapies, it was observed that the Virechana and Nyagrodhadi Ghanavati (combined therapy) provided better relief in the patients of Madhumeha in comparison with Nyagrodhadi Ghanavati (Shamana therapy) alone.
Madhumeha; Prameha; Diabetes mellitus; Shodhana; Virechana; Shamana
The present work was undertaken to study interrelation of Fibrinogen, Lp(a) and LVMI in Type II diabetes patients with or without nephropathy. 100 Type II Diabetic patients attending OPD/IPD of DMC&H, Ludhiana were included. They were divided in two groups. Group I: 50 patients without microalbuminuria (MAU). Group II: 50 patients with MAU. Fibrinogen (Clauss method), Lp(a) and MAU were estimated on Multichannel Autoanalyzer Hitachi-911 (Roche). LVMI was estimated by echocardiography using formula of Devereux and Reicheck. Type II diabetes patients with MAU had significantly raised levels of Fibrinogen, Lp(a), and LVMI as compared to normoalbuminuric diabetics (P < 0.01). Group II patients had positive correlation between Lp(a) and LVMI but no relation between Fibrinogen and LVMI. MAU, marker of microangiopathy, is associated with higher Fibrinogen and Lp(a) levels. This becomes basis of increase cardiovascular risk as demonstrated by higher mean LVMI in Group II patients.
LVMI; Microalbuminuria; Cardiovascular disease